Michael L Gosselin

This inventor holds 17 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 4 EPO patents. Top assignees: Bristol-Myers Squibb Compnay, T Cell Sciences, Inc., Avant Immunotherapeutics, Inc.. Active years: 1995-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael L Gosselin. Retrieved from https://idiyas.com/inventor/michael-l-gosselin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 4)

% Patents Active = 94.1

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 6)

Average Co-Inventor Count = 4.1

ph-index = 7

Forward Citations = 270(Granted Patents)

Location History:

Chelsea, MA (US) (1995 - 1999)
Revere, MA (US) (2000)
Baltimore, MD (US) (2001)
Clinton, CT (US) (2010)
Boston, MA (US) (2015 - 2024)

Company Filing History:

12 out of 3,742

Bristol-Myers Squibb Compnay

patents

2 out of 24

T Cell Sciences, Inc.

patents

1 out of 20

Avant Immunotherapeutics, Inc.

patents

4. 1 out of 2,198

Smithkline Beecham Corporation

patents

5. 2 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 1995-2026

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12534511 - SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS (2026-01-27),

2. 11952420 - Nucleic acids encoding anti-TREM-1 antibodies (2024-04-09),

3. 11919954 - Anti-TREM-1 antibodies and uses thereof (2024-03-05),

4. 11434275 - Fast-off rate serum albumin binding fibronectin type III domains (2022-09-06),

5. 11203630 - Serum albumin-binding fibronectin type III domains (2021-12-21),

6. 11155618 - Anti-TREM-1 antibodies and uses thereof (2021-10-26),

7. 10934572 - Serum albumin binding molecules (2021-03-02),

8. 10766946 - Fast-off rate serum albumin binding fibronectin type III domains (2020-09-08),

9. 10442851 - Serum albumin-binding fibronectin type III domains (2019-10-15),

10. 10221438 - Serum albumin binding molecules (2019-03-05),

11. 9540424 - Serum albumin binding molecules (2017-01-10),

12. 8969289 - Serum albumin binding molecules (2015-03-03),

13. 7820069 - Method and apparatus for controlling contamination from pipe coatings (2010-10-26),

14. 6220747 - Proportional pump system for viscous fluids (2001-04-24),

15. 6057131 - Preparation and use of sialylated glycoforms of soluble complement (2000-05-02),

Title: The Innovative Contributions of Michael L. Gosselin

Introduction

Michael L. Gosselin is a prominent inventor based in Boston, MA, with a remarkable portfolio of 13 patents to his name. His innovative work primarily focuses on therapeutic antibodies and their applications in treating autoimmune diseases. Gosselin's contributions to the field of biotechnology and pharmaceuticals are significant and reflect his commitment to advancing medical science.

Latest Patents

Among his latest patents, Gosselin has developed nucleic acids encoding anti-TREM-1 antibodies. These antibodies specifically bind to and inhibit the TREM-1 signaling pathway, an important mechanism in the inflammatory response. What's noteworthy is that these antibodies do not engage with one or more Fcγ receptors, thus preventing myeloid cells from producing inflammatory cytokines. The implications of this technology extend to therapeutic applications, particularly in the treatment of autoimmune diseases. His other patent, titled "Anti-TREM-1 antibodies and uses thereof," reinforces his focus on this area, outlining similar technologies and their potential benefits.

Career Highlights

Michael L. Gosselin has achieved considerable success throughout his career, notably working with leading companies such as Bristol-Myers Squibb Company. His tenure at such an esteemed organization has allowed him to not only develop his own innovations but also contribute to broader projects in the biotech and pharmaceutical sectors.

Collaborations

In his journey as an inventor, Gosselin has collaborated with notable coworkers such as Tracy S. Mitchell and David Fabrizio. These partnerships have likely enhanced his inventive processes and broadened the scope of his research efforts.

Conclusion

Michael L. Gosselin exemplifies the spirit of innovation within the biotechnology field. His dedication to developing anti-TREM-1 antibodies demonstrates the potential for groundbreaking therapies in treating autoimmune diseases. With a robust portfolio of patents and a career highlighted by significant collaborations, Gosselin continues to make invaluable contributions to medical science.

Profile summary based on public USPTO records.